Nonmotor Symptoms in Vascular and Other Secondary Parkinsonism

Левин, О С; Чимагомедова, А Ш; Skripkina, N.A.; Lyashenko, E A; Babkina, O. V.

doi:10.1016/bs.irn.2017.05.016

Cited by 10 publications

(6 citation statements)

References 119 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, given the long duration of treatment (> 20 years with haloperidol and 3 years with risperidone), it would be unusual for EPS to occur this late, as its onset is typically subacute and mostly occurs within the first 3 months. Additionally, our patient did not exhibit the typical motor symptoms of EPS [22][23][24]26,28]. When applying the diagnostic criteria for drug-induced parkinsonism, our patient does not meet all the requirements.…”

Section: Discussionmentioning

confidence: 71%

“…Mental abnormalities such as emotional blunting, apathy, anhedonia, and social withdrawal can also be observed [23,24,26,27]. Non-motoric symptoms may include cognitive impairment, depression, apathy, orthostatic hypotension, gastrointestinal disorders, urinary symptoms, sleep disorders, and sensory abnormalities or pain [28].…”

Section: Extrapyramidal Symptoms Induced By Antipsychoticsmentioning

confidence: 99%

See 1 more Smart Citation

“It’s a Psychiatric Patient”: Misdiagnosing of Somatic Symptoms in Patients with Mental Disorders Due to Stigma and Inadequate Diagnostic Treatment

Bračko,

Čelofiga

2024

Arch. Psychiatry Res.

View full text Add to dashboard Cite

Aim: People with mental illness have more somatic comorbidities and are frequently mistreated. Misdiagnosis occurs for a variety of reasons, including stigma, poor communication, lack of knowledge of psychiatric pathology, and a tendency to attribute physical symptoms to a mental disorder. Case report: The factors listed above, as well as the unique circumstances of the COVID-19 pandemic led to the misdiagnosis in the case discussed in this paper. The patient was a middle-aged man diagnosed with an ICD-10 diagnosis of a chronic mental disorder in the F2 category and multiple somatic comorbidities in whom amiodarone-induced thyrotoxicosis was undiagnosed and somatic symptoms were attributed to antipsychotic-induced parkinsonism. The mechanism of amiodarone-induced thyrotoxicosis and antipsychotic-induced extrapyramidal symptoms will be described, together with the factors that caused our patient to be misdiagnosed. Conclusion: Psychiatric patients are often specific in their communication and behaviour, therefore interaction must be adapted, with a focus on destigmatizing and educating health workers.

show abstract

Section: Discussionmentioning

confidence: 71%

Section: Extrapyramidal Symptoms Induced By Antipsychoticsmentioning

confidence: 99%

“It’s a Psychiatric Patient”: Misdiagnosing of Somatic Symptoms in Patients with Mental Disorders Due to Stigma and Inadequate Diagnostic Treatment

Bračko,

Čelofiga

2024

Arch. Psychiatry Res.

View full text Add to dashboard Cite

show abstract

“…The features of VP have been accurately described by Levin et al The onset of symptoms can be acute or subacute, usually bilateral, with symptoms of parkinsonian syndrome, a progressive or stable course. Cognitive impairment and dementia, as well as psychiatric disorders, may accompany VP, with an exceptionally low frequency of visual hallucinations (9). Specific features of parkinsonian syndrome in VP may vary in frequency.…”

Section: Vascular Parkinsonismmentioning

confidence: 99%

The effects that secondary parkinsonian syndromes have on health status

Kościołek,

Urbaś,

Misiak

et al. 2024

J Educ Health Sport

View full text Add to dashboard Cite

Introduction and aim of work: The parkinsonian syndrome is a component of Parkinson's disease. A thorough neurological examination can detect symptoms belonging to the parkinsonian syndrome. Diagnosis using the Queen Square Brain Bank criteria is based on the presence of bradykinesia along with one additional symptom in the patient. These include muscle rigidity or resting tremors at a frequency of 4-6 Hz, or postural disturbances that cannot be explained by visual, vestibular, cerebellar, or deep sensory disorders. The parkinsonian syndrome can occur in idiopathic Parkinson's disease, hereditary disorders, secondary parkinsonism, or be part of an atypical parkinsonian syndrome. The aim of the study was to discuss the diagnostic features and differences in the occurrence of the parkinsonian syndrome as a component of Parkinson's disease, both within the context of other neurological disorders. Materials and methods: The foundation of the research was medical articles gathered from the Google Scholar database. The studies were conducted by analyzing keywords such as "parkinsonism," "drug-induced parkinsonism," and "vascular parkinsonism." Results: Secondary parkinsonism, or secondary parkinsonism syndrome, can be indicated by clinical features such as: disease onset below the age of 40, abrupt onset, rapid disease progression, symptoms related to medication use, and symptoms associated with the underlying condition. In addition to clinical evaluation, imaging studies are also employed. Various conditions can lead to the development of secondary parkinsonism, including hydrocephalus, brain tumors, encephalitis, cerebral atherosclerosis, traumatic brain injuries, medications, and poisoning. The aforementioned conditions exert different mechanisms of influence on the central nervous system.

show abstract

“…Some diseases that are associated with dopamine deficiency are accompanied by psychiatric symptoms [6]. Manganese has been reported to accumulate in dopamine neurons in the ventral tegmental area and substantia nigra [7] and is known to cause secondary parkinsonism and psychiatric symptoms, such as hallucinations [8].…”

Section: Introductionmentioning

confidence: 99%

Therapeutic Effects of Quetiapine and 5-HT1A Receptor Agonism on Hyperactivity in Dopamine-Deficient Mice

Ochiai

Fujita

Hagino

et al. 2022

IJMS

View full text Add to dashboard Cite

Some diseases that are associated with dopamine deficiency are accompanied by psychiatric symptoms, including Parkinson’s disease. However, the mechanism by which this occurs has not been clarified. Previous studies found that dopamine-deficient (DD) mice exhibited hyperactivity in a novel environment. This hyperactivity is improved by clozapine and donepezil, which are used to treat psychiatric symptoms associated with dopamine deficiency (PSDD). We considered that DD mice could be used to study PSDD. In the present study, we sought to identify the pharmacological mechanism of PSDD. We conducted locomotor activity tests by administering quetiapine and drugs that have specific actions on serotonin (5-hydroxytryptamine [5-HT]) receptors and muscarinic receptors. Changes in neuronal activity that were induced by drug administration in DD mice were evaluated by examining Fos immunoreactivity. Quetiapine suppressed hyperactivity in DD mice while the 5-HT1A receptor antagonist WAY100635 inhibited this effect. The number of Fos-positive neurons in the median raphe nucleus increased in DD mice that exhibited hyperactivity and was decreased by treatment with quetiapine and 5-HT1A receptor agonists. In conclusion, hyperactivity in DD mice was ameliorated by quetiapine, likely through 5-HT1A receptor activation. These findings suggest that 5-HT1A receptors may play a role in PSDD, and 5-HT1A receptor-targeting drugs may help improve PSDD.

show abstract

Nonmotor Symptoms in Vascular and Other Secondary Parkinsonism

Cited by 10 publications

References 119 publications

“It’s a Psychiatric Patient”: Misdiagnosing of Somatic Symptoms in Patients with Mental Disorders Due to Stigma and Inadequate Diagnostic Treatment

“It’s a Psychiatric Patient”: Misdiagnosing of Somatic Symptoms in Patients with Mental Disorders Due to Stigma and Inadequate Diagnostic Treatment

The effects that secondary parkinsonian syndromes have on health status

Therapeutic Effects of Quetiapine and 5-HT1A Receptor Agonism on Hyperactivity in Dopamine-Deficient Mice

Contact Info

Product

Resources

About